Pakistan’s healthcare system is facing renewed scrutiny after lawmakers expressed serious concerns about the reported circulation of counterfeit medicines and vaccines in rural areas. A Senate committee has called for stronger regulatory oversight, improved enforcement and better coordination between federal and provincial health authorities to address gaps in the pharmaceutical supply chain and immunisation programmes.
During a meeting of the Senate Functional Committee on Problems of Less Developed Areas, chaired by Senator Niaz Ahmed in Islamabad, members questioned the effectiveness of the Drug Regulatory Authority of Pakistan (DRAP) in preventing the circulation of counterfeit pharmaceutical products. The committee also raised concerns about the continued presence of poliovirus in Pakistan and neighbouring Afghanistan.
Following the discussion, the committee directed relevant federal and provincial health authorities to return within 10 days for a dedicated meeting to explain the measures being taken to address the reported problems. The discussion included medicine regulation, vaccine availability, immunisation coverage and difficulties affecting frontline vaccination workers in remote areas.
Government officials informed the committee that a new two-dimensional (2D) barcode tracking system had become operational in October 2026. The system is intended to allow consumers to verify pharmaceutical products through mobile phones and help authorities improve the traceability of medicines.
Officials also confirmed that Pakistan’s proposed National Vaccine Policy was awaiting Cabinet approval. Meanwhile, negotiations were reportedly underway with Russian companies regarding possible joint ventures in insulin and vaccine manufacturing.
The developments have placed medicine safety, public health regulation and vaccine access back in the national spotlight. They are particularly important for rural communities, where access to healthcare services, reliable pharmaceutical distribution and vaccination facilities can present additional challenges.
Senate Committee Raises Alarm Over Counterfeit Medicines and Vaccines
Lawmakers Express Concerns About Weak Pharmaceutical Oversight
The Senate Functional Committee on Problems of Less Developed Areas has expressed serious concern over reports of counterfeit medicines and vaccines circulating in rural parts of Pakistan. The issue was discussed during a meeting held at Parliament Lodges in Islamabad under the chairmanship of Senator Niaz Ahmed.
According to the November 17 report published by Dawn, lawmakers questioned the effectiveness of regulatory oversight and raised concerns about the continued presence of potentially unsafe pharmaceutical products in underserved communities.
The committee’s discussion focused on the responsibilities of DRAP and the need for stronger enforcement mechanisms. The regulator plays an important role in overseeing pharmaceutical products, including their registration, quality, safety and distribution through the regulated supply chain.
Counterfeit medicines represent a significant public health concern because consumers may have difficulty determining whether a product is genuine simply by examining its packaging. Pharmaceutical products that do not meet approved quality requirements can undermine confidence in healthcare services and create additional challenges for patients and healthcare professionals.
However, the concerns raised during the committee meeting should be distinguished from a confirmed nationwide estimate of counterfeit medicines. The available reporting does not provide a verified percentage of pharmaceutical products in rural markets that are counterfeit.
The committee’s intervention reflects the need for authorities to investigate complaints, improve monitoring and explain how existing regulatory systems are being implemented.
Federal and Provincial Health Authorities Given 10 Days to Respond
The Senate committee directed relevant federal and provincial health authorities to attend a follow-up meeting within 10 days to discuss the reported regulatory gaps and provide details of corrective measures.
The proposed meeting is expected to involve the Drug Regulatory Authority of Pakistan, the Federal Directorate of Immunisation and representatives of provincial health departments.
The committee wants the relevant institutions to explain how they are addressing counterfeit medicines, vaccine-related concerns and weaknesses in the existing enforcement system.
The discussion also extends beyond pharmaceutical regulation. Lawmakers raised concerns about the salaries and working conditions of immunisation field staff operating in remote areas, particularly in Khyber Pakhtunkhwa and Balochistan.
These workers are important to vaccination campaigns because they help health authorities reach children and families in locations where healthcare facilities may be limited or difficult to access.
The 10-day deadline creates an opportunity for the concerned departments to present information about existing arrangements, outstanding problems and proposed improvements.
It is important to note that the committee’s direction is a request for official explanations and follow-up action. It does not, by itself, establish that all the identified problems have already been resolved or that a new enforcement policy has been implemented.
The outcome of the follow-up meeting will be important in determining whether the concerns lead to specific administrative and regulatory measures.
DRAP’s 2D Barcode System Introduces a New Method of Medicine Verification
Mobile Phone Scanning Intended to Help Consumers Check Pharmaceutical Products
One of the major developments discussed during the Senate meeting was the introduction of a two-dimensional barcode tracking system for pharmaceutical products.
Officials from the Ministry of National Health Services informed lawmakers that the system had become operational in October 2026. The technology is designed to allow consumers to verify medicine authenticity through mobile phones by scanning the barcode printed on pharmaceutical packaging.
The system is connected to the wider effort to improve traceability across Pakistan’s pharmaceutical supply chain. It is intended to help consumers access relevant product information and enable regulatory authorities to identify and monitor pharmaceutical products more effectively.
A 2D barcode can contain or connect to information that is not available through an ordinary visual inspection of a medicine package. Depending on the information recorded in the system, verification can help users check product details and support efforts to identify discrepancies.
The initiative is also relevant to manufacturers, importers, distributors, pharmacies and regulatory inspectors. A functioning tracking system can help improve the ability of authorities to follow pharmaceutical products through different stages of distribution.
Officials told the committee that the system would be formally inaugurated by the prime minister at a later stage. However, the reported operational date indicates that the regulatory framework and technical arrangements had already entered into effect before the formal ceremony.
The system’s effectiveness will ultimately depend on accurate product registration, compliance by manufacturers and importers, reliable data and regular enforcement.
Track-and-Trace Technology Can Improve Supply Chain Transparency
Medicine traceability is an important part of pharmaceutical regulation because products move through several stages before reaching consumers.
Manufacturers produce medicines, importers bring products into the country, distributors supply wholesalers and pharmacies, and retailers make the products available to patients. At each stage, accurate records can help regulators monitor the movement of pharmaceutical products.
The 2D barcode initiative is intended to strengthen this process by linking products to information that can be checked through a digital system.
According to reporting published by Dawn on November 10, the Ministry of National Health Services previously stated that approximately 800 pharmaceutical companies and more than 90,000 medicines were registered with DRAP. The centralised track-and-trace system had become operational on October 9, 2026, according to that report.
A digital tracking mechanism can also support investigations when a product is reported to have quality problems. If relevant information is available, authorities may be able to identify the product, examine its distribution history and take appropriate regulatory action.
However, technology alone cannot eliminate counterfeit medicines. The system requires accurate records, compliance from regulated businesses, effective inspections and action against individuals or companies involved in unlawful activities.
It also requires public awareness. Consumers need to understand how to use the verification facility and what steps to take when product information does not match the details displayed on the packaging.
The new system therefore represents an important regulatory development, but its success will depend on consistent implementation throughout the pharmaceutical supply chain.
Rural Communities Face Additional Challenges in Accessing Safe Medicines
Limited Healthcare Access Can Make Pharmaceutical Oversight More Difficult
Rural communities often depend on a combination of government health facilities, private clinics, local pharmacies and medicine distributors to obtain healthcare products.
The availability of these services can vary significantly between districts and villages. Some communities are located far from major hospitals and regulatory offices, making regular monitoring and access to healthcare services more challenging.
In such circumstances, consumers may have fewer opportunities to compare pharmaceutical products or seek information from qualified healthcare professionals.
The concerns raised by the Senate committee are therefore particularly relevant to less developed areas, where reliable medicine distribution and regulatory supervision are essential.
Counterfeit medicine concerns cannot be addressed through public awareness alone. Authorities need effective inspection systems, reliable product registration and the ability to investigate suspicious supplies.
Healthcare facilities and pharmacies also have an important role in maintaining proper procurement and storage practices. Pharmaceutical products must be handled according to applicable requirements, and businesses must obtain supplies through legitimate channels.
The government can strengthen the system by improving coordination between DRAP, provincial drug control authorities, district administrations and healthcare institutions.
Better communication between these organisations would help authorities identify areas where medicine supply problems are being reported and determine whether further inspection or regulatory action is required.
The current Senate discussion highlights the importance of treating rural pharmaceutical safety as a public health priority rather than limiting regulatory attention to major cities.
Medicine Quality Concerns Can Undermine Public Confidence
Public confidence is an important part of an effective healthcare system. Patients need to trust that medicines supplied through legitimate healthcare channels meet the required standards.
When reports of counterfeit or substandard products emerge, consumers may become uncertain about the safety of medicines available in local markets.
Such uncertainty can also affect confidence in healthcare institutions, pharmacies and vaccination programmes. Authorities therefore need to communicate clearly about regulatory procedures and provide accessible methods for verifying pharmaceutical products.
Public awareness campaigns can explain the importance of purchasing medicines from legitimate pharmacies, checking packaging information and using official verification services where available.
At the same time, awareness messages should avoid creating unnecessary fear. The existence of counterfeit products is a reason for stronger regulation and informed purchasing, not a reason to assume that every medicine available in a rural pharmacy is unsafe.
Consumers should not make treatment decisions based solely on social media messages or unverified claims about pharmaceutical products.
When a medicine appears suspicious or its details cannot be verified, consumers can seek clarification from a qualified pharmacist or healthcare professional and use the relevant official reporting channels.
A transparent regulatory system should also communicate the results of investigations and explain what action has been taken against confirmed violations.
These measures can help maintain confidence while ensuring that reported concerns receive appropriate attention.
Pakistan’s National Vaccine Policy Awaits Cabinet Approval
Government Officials Confirm Policy Remains Under Consideration
Another important issue discussed during the Senate committee meeting was the proposed National Vaccine Policy.
Officials informed lawmakers that the policy was awaiting approval from the federal Cabinet. The development is significant because a national policy can provide a coordinated framework for vaccination planning, programme management and cooperation between different levels of government.
Pakistan’s immunisation system involves federal institutions, provincial health departments, international partners and frontline vaccination workers.
A national policy can help define responsibilities, establish priorities and support consistent planning across different regions.
The Senate discussion also highlighted the need to improve vaccine access and address problems affecting immunisation services in remote communities.
Although officials confirmed that the policy was awaiting Cabinet approval, the available reporting does not establish a final approval date or provide a complete account of every provision included in the proposed document.
The policy should therefore be described as awaiting approval rather than an already implemented national framework.
Its eventual approval and implementation could be important for improving coordination between vaccination programmes, strengthening public awareness and supporting the availability of essential vaccines.
The government will also need to ensure that policy decisions are translated into practical arrangements at provincial and district levels.
Policy Coordination Can Strengthen Vaccination Planning
Vaccination programmes require continuous coordination because immunisation involves multiple activities, including vaccine procurement, storage, transportation, distribution, administration and monitoring.
A policy framework can help establish how these activities should be coordinated and how responsibilities should be shared between relevant institutions.
It can also support the development of long-term plans for vaccine availability and domestic manufacturing.
The Senate committee’s discussion indicates that policymakers are considering both immediate public health concerns and broader institutional improvements.
However, policy approval is only one stage of implementation. Once a policy receives Cabinet approval, relevant departments must develop operational arrangements, allocate resources and establish mechanisms for monitoring progress.
Provincial governments also need to ensure that vaccination services reach communities with different geographical and administrative conditions.
Remote areas may require additional logistical planning because health workers must travel longer distances and maintain contact with communities that are not located near major healthcare facilities.
A coordinated national approach could help identify these difficulties and develop practical solutions.
The proposed policy’s effectiveness will therefore depend on its implementation, available resources, institutional accountability and the ability of health authorities to reach children and other eligible groups consistently.
Pakistan’s Immunisation Programme Targets 7.3 Million Children Annually
Expanded Programme on Immunisation Covers 13 Vaccine-Preventable Diseases
The Federal Directorate of Immunisation briefed the Senate committee on the history and progress of Pakistan’s Expanded Programme on Immunisation.
The programme, established in 1978, is one of the country’s major public health initiatives. According to information presented during the committee meeting, it targets an annual cohort of approximately 7.3 million children and covers 13 vaccine-preventable diseases.
The programme is designed to protect children through routine vaccination and organised immunisation activities.
Vaccination programmes are particularly important during childhood because they help prevent diseases that can cause serious illness and place additional pressure on families and healthcare facilities.
The programme’s national scale means that it requires coordination across provinces, districts, health facilities and community-level services.
Frontline health workers play an important role in this process. They help identify eligible children, communicate with families, administer vaccines through authorised services and maintain programme records.
The annual target of 7.3 million children demonstrates the scale of the immunisation effort and the importance of maintaining sufficient supplies, trained personnel and effective delivery arrangements.
The committee’s review also highlights the need to examine how vaccination services are performing in different regions rather than relying only on national-level figures.
Differences in access, local infrastructure and community engagement can influence how effectively programmes reach eligible children.
Immunisation Coverage Figures Highlight Progress and Remaining Gaps
The Senate committee was also briefed on national immunisation coverage and developments in reaching children who had previously missed routine vaccinations.
According to figures reported by The News on November 17, national immunisation coverage stood at approximately 80 to 81 percent.
The report stated that Azad Jammu and Kashmir had recorded coverage of 93 percent, while Punjab’s coverage stood at 90 percent.
Officials also informed the committee that the number of zero-dose children had declined from approximately 400,000 to 160,000 over the preceding three years.
Zero-dose children are generally those who have not received the first dose of a routine vaccine included in the relevant immunisation programme. Identifying these children is important because they may face greater barriers to accessing routine vaccination services.
The reported reduction indicates progress in reaching previously underserved populations, although the remaining number shows that further work is required.
The figures also demonstrate why national averages should be considered alongside regional information. A province or district with lower coverage may require additional health workers, better transport arrangements or targeted community engagement.
Coverage estimates depend on the definitions and measurement methods used by health authorities. They should therefore be interpreted according to the reporting period and official programme data.
Continued monitoring will be necessary to determine whether the improvements are sustained and whether children in remote communities are receiving the required routine vaccinations.
Polio Remains a Major Public Health Concern for Pakistan
Senate Members Question Continued Poliovirus Transmission
The continued presence of poliovirus in Pakistan was another major issue discussed during the Senate committee meeting.
Lawmakers expressed concern that Pakistan and neighbouring Afghanistan remain the countries where wild poliovirus continues to circulate.
The persistence of the disease has raised questions about the challenges facing eradication efforts despite years of vaccination campaigns and public health interventions.
Polio is a highly infectious viral disease that primarily affects young children and can cause permanent paralysis. Vaccination remains the principal method of preventing the disease and protecting communities.
Pakistan has conducted repeated national and subnational vaccination campaigns to reach children who may have missed routine immunisation or remain vulnerable because of gaps in campaign coverage.
However, reaching every eligible child can be difficult in areas affected by geographical isolation, population movement, insecurity, misinformation and limited healthcare infrastructure.
The Senate committee’s discussion placed renewed attention on the need for better coordination between health departments and stronger efforts to reach communities that remain outside regular vaccination services.
The committee also sought information about the effectiveness of existing immunisation arrangements and the continuing challenges associated with polio eradication.
The issue requires sustained attention because transmission in one area can create risks for other communities through population movement.
Cross-Border Cooperation and Community Engagement Remain Important
Pakistan and Afghanistan share a long border and have populations that move between different areas for family, economic and other reasons.
This movement makes coordination between the two countries important for polio surveillance and vaccination activities.
Public health authorities need to exchange relevant information, identify possible transmission risks and maintain vaccination efforts among communities that move across geographical boundaries.
Cross-border cooperation can help reduce gaps in immunisation coverage and improve the ability of health programmes to respond to reported cases or environmental surveillance findings.
Community engagement is equally important. Parents and caregivers need clear information about the importance of vaccination, the diseases it prevents and the availability of authorised vaccination services.
Health workers and community representatives can help address concerns by providing reliable information in local languages and explaining vaccination arrangements.
The Senate committee’s concerns indicate that lawmakers want a more effective response to the continued presence of poliovirus and the broader weaknesses affecting vaccination services.
However, eradication requires more than a single campaign or policy announcement. It depends on consistent vaccination coverage, reliable surveillance, trained staff, sufficient vaccine supplies and cooperation between relevant authorities.
The progress of immunisation programmes will therefore remain an important measure of Pakistan’s public health response.
Government Explores Local Insulin and Vaccine Manufacturing

Negotiations With Russian Companies Focus on Possible Joint Ventures
Officials informed the Senate committee that negotiations were underway with Russian companies regarding possible joint ventures in insulin and vaccine manufacturing.
The discussions indicate that Pakistan is exploring opportunities to strengthen local pharmaceutical production and reduce dependence on imported products in selected areas.
Insulin is an essential medicine used in the management of diabetes, while vaccines are important tools for preventing infectious diseases.
Developing domestic manufacturing capacity could support the availability of these products, provided that production facilities meet the required quality, safety and regulatory standards.
International partnerships can potentially provide access to technical expertise, manufacturing processes and investment opportunities.
However, negotiations should not be confused with a completed agreement. The November 17 reporting did not confirm a final investment amount, signed joint venture agreement, manufacturing location or production timetable.
The discussions are therefore at a stage that requires further official information before any specific outcome can be presented as confirmed.
Any future manufacturing arrangement would also need to comply with the applicable pharmaceutical regulations and quality requirements.
Local production can contribute to pharmaceutical security, but manufacturing capacity must be supported by reliable raw materials, skilled personnel, quality control systems and effective distribution.
The government will need to communicate further details if negotiations progress towards formal agreements.
Domestic Production Could Support Long-Term Pharmaceutical Security
Pakistan’s interest in local insulin and vaccine production reflects a broader discussion about the country’s pharmaceutical supply chain.
Dependence on external suppliers can create challenges when international prices change, transportation is disrupted or products become difficult to obtain.
Domestic manufacturing may provide additional supply options and support the development of local technical expertise.
However, the benefits depend on whether locally manufactured products can meet regulatory standards and remain affordable for patients and public health programmes.
Vaccine manufacturing is particularly complex because it requires specialised facilities, quality assurance systems, technical knowledge and strict production controls.
The same principle applies to insulin and other pharmaceutical products that require consistent manufacturing standards.
International partnerships may help address some technical and investment requirements, but they do not remove the need for strong national regulation.
DRAP and other relevant institutions would have important responsibilities in ensuring that products manufactured locally meet the required standards before entering the market.
The reported negotiations with Russian companies therefore represent a potential development rather than a completed manufacturing initiative.
Further information about agreements, investment, technology transfer and production plans will be necessary to assess the project’s likely contribution to Pakistan’s pharmaceutical sector.
Frontline Vaccination Workers in Remote Areas Require Better Support
Senate Committee Highlights Employment and Salary Concerns
The Senate committee also raised concerns about the salaries and working conditions of immunisation field staff serving in remote parts of Khyber Pakhtunkhwa and Balochistan.
Frontline vaccination workers are essential to public health programmes because they help deliver immunisation services beyond major hospitals and urban healthcare facilities.
Their responsibilities can include visiting communities, identifying eligible children, coordinating vaccination activities and maintaining records of programme coverage.
In remote districts, these tasks can require additional travel and coordination because settlements may be spread across large geographical areas.
The availability of trained and motivated staff is therefore important for maintaining routine immunisation and organised vaccination campaigns.
If field workers face delayed payments, uncertain employment arrangements or inadequate operational support, programme management may become more difficult.
The committee’s discussion reflects concerns about whether the current arrangements provide sufficient support to workers responsible for delivering essential public health services.
The issue is particularly relevant to areas where access to healthcare is already limited and where vaccination teams may have to overcome additional logistical challenges.
The committee has included these concerns in the matters that relevant departments are expected to address during the follow-up meeting.
Staff Welfare and Operational Support Can Improve Programme Delivery
A successful immunisation programme depends not only on vaccines and policy decisions but also on the people responsible for delivering services.
Field workers need clear employment arrangements, timely payment, appropriate training and operational support to perform their responsibilities effectively.
They also require reliable transport and coordination arrangements where geographical conditions make community visits difficult.
Provincial health departments can contribute by identifying staffing gaps, reviewing payment arrangements and ensuring that frontline teams have the resources required for vaccination activities.
Federal institutions can support these efforts through coordination, programme planning and the allocation of relevant resources.
The committee’s decision to revisit staff-related concerns alongside medicine regulation and polio eradication reflects the connection between institutional capacity and public health outcomes.
Improving staff conditions is not simply an administrative matter. It can also influence the ability of vaccination programmes to reach children and maintain consistent coverage.
Further information from the relevant authorities will be needed to establish the scale of the salary and employment issues and identify the measures proposed to resolve them.
Stronger DRAP Enforcement and Public Awareness Needed to Protect Consumers
Regulatory Inspections Must Support the New Digital Tracking System
The introduction of the 2D barcode system provides an additional tool for monitoring pharmaceutical products, but the system needs to operate alongside effective regulatory inspections.
DRAP and relevant provincial authorities have responsibilities for ensuring that pharmaceutical products meet applicable legal and quality requirements.
Digital records can support these responsibilities by improving traceability, but inspectors still need to examine suspected violations and investigate complaints.
The authorities must also ensure that manufacturers, importers and other regulated businesses comply with the relevant barcode and serialization requirements.
The November 10 DRAP-related reporting highlighted the importance of the centralised tracking system and the need for pharmaceutical companies to maintain accurate product information.
Regulatory enforcement should focus on identifying non-compliant products, investigating suspicious distribution practices and taking action where violations are established.
Authorities also need accessible complaint mechanisms so that consumers and healthcare professionals can report concerns.
The Senate committee’s request for a follow-up meeting provides an opportunity for DRAP and provincial health departments to explain how inspections, tracking technology and enforcement activities are being coordinated.
The effectiveness of these measures should be assessed through implementation data and documented regulatory action rather than announcements alone.
Consumers Need Clear Information About Medicine Verification
Public awareness is an important part of preventing the circulation of counterfeit pharmaceutical products.
Consumers should be informed about official medicine verification facilities and the importance of obtaining pharmaceutical products through legitimate healthcare channels.
The Ministry of National Health Services previously highlighted DRAP’s Mehfooz Dawa application and the track-and-trace system as tools for checking medicine information.
Where available, consumers can use official verification facilities to examine product details and seek clarification if information appears inconsistent.
However, barcode verification should not be treated as the only measure of medicine safety. A barcode is one part of a broader regulatory system, and consumers should not assume that a product is safe solely because a code can be scanned.
Similarly, the absence of a barcode alone should not automatically be treated as proof that a medicine is counterfeit. Product requirements and applicable transition arrangements must be considered.
Consumers who have concerns about a medicine should seek clarification from a qualified pharmacist or healthcare professional and use official regulatory reporting channels where appropriate.
Authorities should provide simple instructions about the verification process, the information displayed by the system and the steps consumers can take when a product raises concerns.
Clear communication can help people use the new technology without creating unnecessary confusion or fear.
Public Health Reforms Require Coordination and Accountability
Federal and Provincial Institutions Must Work Together
The Senate committee’s discussion demonstrates that medicine regulation, vaccine policy and immunisation delivery are connected areas of public health administration.
DRAP oversees important aspects of pharmaceutical regulation, while the Federal Directorate of Immunisation coordinates major immunisation activities. Provincial health departments are also central to delivering services and addressing local implementation challenges.
These institutions need to work together to identify gaps and establish clear responsibilities.
For example, medicine traceability requires cooperation between regulators and pharmaceutical businesses. Vaccination coverage depends on coordination between federal programmes, provincial departments and frontline workers.
The challenges affecting rural communities may also require district-level planning because healthcare access, transportation and staffing conditions differ from one area to another.
The committee’s direction for a meeting within 10 days provides a formal opportunity to bring relevant institutions together and examine these issues.
A useful follow-up response would include clear information about the implementation of the barcode system, medicine inspection arrangements, vaccine availability, staff-related concerns and measures for reaching underserved populations.
The effectiveness of the response will depend on whether departments provide complete information and take practical steps to address identified problems.
Transparent Reporting Can Help Measure Progress
Public health reforms require measurable results and regular reporting.
Authorities can strengthen accountability by publishing relevant information about pharmaceutical inspections, confirmed regulatory violations, product recalls, vaccine availability and immunisation coverage.
Such information would help policymakers, healthcare professionals and the public understand whether existing initiatives are producing measurable improvements.
The 2D barcode system, for example, should be assessed through information about regulatory compliance, product registration and the effectiveness of verification arrangements.
Similarly, immunisation programmes should be evaluated through coverage data, the number of children reached and progress in identifying communities that remain underserved.
Public reporting should distinguish between confirmed results, provisional figures and future targets.
This distinction is particularly important when discussing counterfeit medicines. Concerns raised by lawmakers deserve attention, but reliable public data are necessary to establish the scale and geographical distribution of the problem.
The same principle applies to proposed manufacturing agreements and the National Vaccine Policy. Negotiations and pending approvals should not be presented as completed achievements.
Transparent reporting can help maintain public confidence and allow parliamentary committees to assess whether departments are meeting their responsibilities.
Outlook for Medicine Safety and Vaccination in Pakistan
The Next 10 Days Will Be Important for Government Accountability
The Senate committee’s decision to summon federal and provincial health authorities within 10 days has created an immediate opportunity for officials to respond to concerns about medicine regulation and vaccination services.
The follow-up meeting is expected to examine the reported circulation of counterfeit medicines and vaccines, weaknesses in regulatory enforcement, staff-related issues in remote areas and the continuing challenge of polio eradication.
The relevant departments will need to explain what measures are already in place and where further action is required.
The barcode tracking system is an important development, but its effectiveness will depend on consistent implementation, accurate information and public awareness.
The National Vaccine Policy also remains an important pending matter. Cabinet approval and subsequent implementation could help strengthen coordination across the country’s immunisation system.
Meanwhile, negotiations concerning possible joint ventures in insulin and vaccine manufacturing may provide opportunities for future domestic production, although no completed agreement was confirmed in the reporting available on November 17.
The coming weeks will therefore be important for determining how the government responds to the concerns raised by lawmakers.
Long-Term Improvements Will Depend on Effective Implementation
Pakistan’s medicine safety and immunisation challenges require a coordinated response involving regulation, healthcare delivery, pharmaceutical manufacturing and public awareness.
Digital tracking can improve the ability to verify products, but effective inspections and enforcement remain necessary.
A national vaccine policy can provide a framework for coordination, but its success will depend on resources, implementation and cooperation between federal and provincial institutions.
Likewise, improving immunisation coverage requires reliable vaccine supplies, trained staff, community engagement and services that reach children in remote areas.
The concerns raised by the Senate committee should therefore be viewed as part of a broader discussion about the quality and accessibility of healthcare services in Pakistan.
The country has an established immunisation programme and has reported progress in reaching previously unvaccinated children. At the same time, the continued presence of polio and concerns about pharmaceutical regulation demonstrate that important challenges remain.
The priority should be to turn parliamentary directions and government initiatives into measurable improvements for consumers and patients.
Conclusion: Concerns over counterfeit medicines and vaccines in rural Pakistan have prompted the Senate to demand urgent explanations from federal and provincial health authorities within 10 days. The introduction of a 2D barcode tracking system, the pending National Vaccine Policy and discussions about local pharmaceutical manufacturing represent important developments. However, stronger regulatory enforcement, reliable medicine distribution, support for frontline vaccination workers and continued immunisation efforts will be essential to improving public health protection across the country.
